Poster presentations to feature research on leveraging artificial intelligence and machine learning methods to decode the gut-brain axis, innate immunity,.
InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
May 11, 2021 08:10 ET | Source: InveniAI LLC InveniAI LLC Guilford, Connecticut, UNITED STATES
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseases
Dr. Alesci’s proven track record in optimizing early-stage drug development of multiple programs in various therapeutic areas will be key as the company leverages its AI-platform to advance and diversify its portfolio
GUILFORD, Conn., May 11, 2021 (GLOBE NEWSWIRE) InveniAI
® LLC, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, announced today the appointment of Sa
InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.